Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2

Hereditary hemorrhagic telangiectasia (HTT) is an autosomal dominant disease, most frequently caused by a mutation in either ENG or ACVRL1, which can be associated with pulmonary arterial hypertension (PAH). In this report, we describe a new unpublished ACVRL1 mutation segregating in three members of the same family, showing three different types of pulmonary hypertension (PH) in the absence of BMPR2 mutations. The first patient has a form of heritable PAH (HPAH) in the absence of hepatic arteriovenous malformations (AVMs); the second one has a severe form of portopulmonary hypertension (PoPAH) associated with multiple hepatic AVMs; the third one has hepatopulmonary syndrome (HPS) with numerous hepatic arteriovenous fistulas and a form of post-capillary PH due to high cardiac output. In summary, a single mutation in the ACVRL1 gene can be associated, in the same family, with an extreme phenotypic variability regarding not only the clinical presentation of HHT but also the type of PH in the absence of BMPR2 mutations. More studies are needed to evaluate if this variability can be explained by the presence of additional variants in other genes relevant for the pathogenesis of HHT.

[1]  N. Lamblin,et al.  Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability , 2017, PloS one.

[2]  B. Ni,et al.  Critical effects of epigenetic regulation in pulmonary arterial hypertension , 2017, Cellular and Molecular Life Sciences.

[3]  C. Fischer,et al.  Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. , 2016, Clinical science.

[4]  M. Ramsay,et al.  International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. , 2016, Transplantation.

[5]  M. Freire,et al.  High prevalence of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2013, European journal of internal medicine.

[6]  J. Saurin,et al.  Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences. , 2013, European journal of internal medicine.

[7]  H. Tighiouart,et al.  Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. , 2010, Gastroenterology.

[8]  D. Tregouet,et al.  Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. , 2010, American journal of respiratory and critical care medicine.

[9]  T. van Groen,et al.  Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. , 2009, Gastroenterology.

[10]  E. Buscarini,et al.  Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia , 2006, Genetics in Medicine.

[11]  R. Rodríguez-Roisín,et al.  Pulmonary–Hepatic vascular Disorders (PHD) , 2004, European Respiratory Journal.

[12]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[13]  A. Guttmacher,et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.

[14]  J. G. Walker,et al.  Arterial changes in the lungs in cirrhosis of the liver--lung spider nevi. , 1966, The New England journal of medicine.

[15]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.